Pizer recalls 4.2 million tablets of Nurtec ODT prescription drugs
Packaging of the product fails to meet the child resistant packaging requirement
Biohaven Pharmaceuticals of New Haven, Conn. and Pfizer of N.Y., are recalling about 4.2 million Nurtec ODT (rimegepant) orally disintegrating tablets.
The packaging of the prescription drugs is not child resistant, posing a risk of poisoning.
No incidents or injuries are reported.
This recall involves prescription drugs Nurtec ODT 75 mg orally disintegrating tablets sold in cartons containing one blister card of 8 tablets, all dates through 6/2026 and NDC number72618-3000-2.
The tablets are in a non-child-resistant blister card packaged in a carton that includes the name of the product, dosage strength, NDC number and expiration date.
The dosage strength and expiration date are printed or stamped on the blister card.
The tablets, manufactured in the U.S., were sold at pharmacies nationwide as a prescribed medicine from December 2021, through March 2023.
The prices of the product are varied based on health insurance terms and other factors.
What to do
Consumers should immediately place the recalled product out of the sight and reach of children and contact Pfizer for a free child resistant pouch to store the product.
Once the product is secured, consumers can continue to use it as directed.
Consumers may contact Pfizer at (800) 879-3477 Monday through Friday 9 a.m. to 7 p.m. (ET) or online at www.Nurtec.com/PackagingUpdate for more information.